Cloretazine for the treatment of acute myeloid leukemia.

Cloretazine for the treatment of acute myeloid leukemia. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Cloretazine for the treatment of acute myeloid leukemia. Abstract Text:

Norbert Vey,Frank Giles,

Cloretazine is a new sulfonylhydrazine alkylating agent with antileukemic activity. Phase I studies have shown myelosuppression to be the dose limiting toxicity in both solid tumors and leukemias. A large Phase II study of single agent cloretazine (600 mg/m2) confirmed its activity in patients with relapsed acute myeloid leukemia, and in elderly patients with previously untreated acute myeloid leukemia or myelodysplastic syndrome. It also confirmed the limited nonhematological toxicity, even in elderly patients. Cloretazine can be safely combined with cytarabine, and this combination regimen is currently being tested in a large Phase III study in patients with relapsed acute myeloid leukemia. Cloretazine is a promising new antileukemic agent that may be incorporated into an intensive combination regimen.

Cloretazine for the treatment of acute myeloid leukemia. Publishing Authors By Initials

N Vey,F Giles,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Cloretazine for the treatment of acute myeloid leukemia. Journal Published:

PUBLICATION TYPE: Review

Journal: Expert review of anticancer therapy

VOLUME: 6

Page Numbers: 321-8

Journal Abbreviation: Expert Rev Anticancer Ther

ISSN: 1744-8328

DAY: 5

MONTH: Mar

YEAR: 2006

Cloretazine for the treatment of acute myeloid leukemia. Information

Number of References: 65

LANGUAGE: eng

NlmUniqueID: 101123358

Cloretazine for the treatment of acute myeloid leukemia. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Cloretazine for the treatment of acute myeloid leukemia. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Cloretazine for the treatment of acute myeloid leukemia.

AFFILIATION: Department of Hematology, Institut Paoli-Calmettes, 232 Blvd Sainte Marguerite, 13009 Marseille, France. veyn@marseille.fnclcc.fr

Country: England

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Expert Rev Anticancer Ther

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Cloretazine for the treatment of acute myeloid leukemia Related Publications

• A perspective on telmisartan and cardiovascular risk.
• Adverse childhood experiences and childhood autobiographical memory disturbance.
• Adverse childhood experiences and prescribed psychotropic medications in adults.
• Allele-specific regulation of primary cilia function by the von Hippel-Lindau tumor suppressor.
• Assessing adaptive behaviour in the post-acute setting following traumatic brain injury: initial reliability and validity of the Adaptive Behaviour and Community Competency Scale (ABCCS).
• Bayesian inference for stochastic epidemic models with time-inhomogeneous removal rates.
• Blood pressure-the better biomarker: delay in clinical application.
• Brain stem gliomas: Patterns of Care in Victoria from 1998-2000.
• Cloretazine for the treatment of acute myeloid leukemia.
• Computational capabilities of recurrent NARX neural networks.
• Expression and regulation of anti-mullerian hormone in an oviparous species, the hen.
• Financial implications of plans to combat methicillin-resistant Staphylococcus aureus (MRSA) in an orthopaedic department.
• Hormone therapy and breast cancer: what factors modify the association?
• Institution of universal screening for Group B streptococcus (GBS) from a risk management protocol results in reduction of early-onset GBS disease in a tertiary obstetric unit.
• Is cancer risk associated with anger control and negative affect? Findings from a prospective cohort study.
• Learning long-term dependencies in NARX recurrent neural networks.
• Nelarabine activity in acute biphenotypic leukemia.
• Nicotine in blood in relation to smoking.
• Occupational exposure to ionizing and non-ionizing radiation and risk of glioma.
• On the distribution of performance from multiple neural-network trials.
• Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies.
• RECENT CASES OF DENTAL MALPRACTICE.
• Recurrent ectopic pregnancy.
• The cardiometabolic syndrome and calcium channel blocker combination drugs.
• The enduring effects of abuse and related adverse experiences in childhood : A convergence of evidence from neurobiology and epidemiology.
• The management of primary cutaneous melanoma in Victoria in 1996 and 2000.
• The oxygen effect on radiation-induced chromosome aberrations: breakage-versus-recombination hypotheses.
• The rs743572 common variant in the promoter of CYP17A1 is not associated with prostate cancer risk or circulating hormonal levels.
• The von Hippel-Lindau tumour suppressor interacts with microtubules through kinesin-2.
• Treatment of acute lymphoblastic leukaemia : a new era.